Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
July 01, 2022 08:40 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
June 06, 2022 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation...
Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
June 05, 2022 07:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation...
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 02, 2022 06:29 ET
|
Centessa Pharmaceuticals plc
- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study - - Discontinuation of lixivaptan development expected to...
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates
May 16, 2022 07:00 ET
|
Centessa Pharmaceuticals plc
– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022 to highlight LB101...
Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
March 30, 2022 16:01 ET
|
Centessa Pharmaceuticals plc
– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022...
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
March 23, 2022 16:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim...
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
March 07, 2022 07:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to...
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
February 24, 2022 07:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today...
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application
December 14, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the...